Singapore sets global benchmark for regulating medical devices and digital health

Singapore has become the first country to achieve the World Health Organization’s highest regulatory classification for medical devices. 

Singapore sets global benchmark for regulating medical devices and digital health

Singapore has become the first country in the world to achieve the highest regulatory maturity level for medical devices under the World Health Organization’s global benchmarking system.

Announced on 10 March 2026, the milestone recognises the work of Singapore’s Health Sciences Authority (HSA), which reached Maturity Level 4 (ML4) under the WHO’s Global Benchmarking Tool Plus for medical devices. The designation is the highest classification available for national regulatory authorities overseeing medical products.

While the announcement relates to Singapore’s regulatory system, it highlights a broader global challenge: ensuring that rapidly evolving medical technologies, including digital health tools increasingly used in home care and community health services, are safe, effective and reliable.

For policymakers, technology developers and care providers in the UK care sector, the development underlines the growing importance of strong regulation as digital health becomes more embedded in everyday care delivery.

Why medical device regulation matters

Medical devices are no longer confined to hospital equipment. Today they increasingly include digital tools such as remote monitoring platforms, wearable health sensors and software used to support diagnosis or treatment.

Many of these technologies are now being used beyond hospitals, supporting care delivered in people’s homes or community settings. As a result, regulators must ensure these tools are assessed not only before they reach the market but throughout their lifecycle, including monitoring performance once they are widely used.

The WHO said Singapore’s ML4 designation confirms that its regulatory system operates at an advanced level and includes mechanisms for continuous improvement. This includes oversight of product approval, clinical evaluation and post-market surveillance.

Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, said effective regulation is essential for maintaining trust in health technologies.

“Effective regulation is essential to ensure that health products, including medical devices, reaching patients are safe, effective and of assured quality,” she said.

“Singapore’s achievement reflects an exceptional commitment to regulatory excellence and demonstrates how sustained investment in regulatory capacity can protect populations, support innovation and strengthen trust in medical technologies.”

Singapore’s role in global medical technology

Singapore has developed into a major international hub for medical technology innovation. Around 200 manufacturers operate in the country, producing a wide range of devices including diagnostics, monitoring tools and software-based medical technologies.

Strong regulatory systems can help support this innovation by providing clear approval pathways and ensuring products meet recognised safety standards.

Adjunct Professor (Dr) Raymond Chua, chief executive of the Health Sciences Authority, said the ML4 classification reflects years of investment in regulatory capability.

“It is a great honor for Singapore’s Health Sciences Authority to be recognized at the highest WHO Maturity Level classification for medical device regulation,” he said.

“This milestone reflects HSA’s sustained effort to build a robust and forward-looking regulatory system that safeguards patients while enabling timely access to innovative health products.”

Singapore previously achieved the WHO’s highest maturity level for medicines regulation in 2022. Its regulatory authority was later recognised as a WHO Listed Authority for medicines, meaning other countries can rely on its evaluations when approving certain health products.

A global challenge for health regulators

Despite progress in some countries, regulatory capacity remains uneven worldwide. The WHO estimates that only around 32% of regulatory authorities currently have the ability to fully ensure that health products meet required standards of safety, quality and effectiveness.

As digital health tools and connected medical devices become more common, this gap is becoming more significant.

Software-based medical technologies can be deployed across multiple countries simultaneously, making international regulatory coordination increasingly important. Singapore’s regulatory authority plays a role in several global initiatives designed to improve alignment between regulators.

Relevance for the UK care sector

The issue of medical device oversight is particularly relevant for the UK care sector as digital health technologies continue to expand.

Across community health services and social care settings, tools such as remote monitoring systems, digital medication platforms and virtual consultations are becoming more common. Many of these technologies fall under the category of medical devices or software used for medical purposes.

As home care technology becomes more sophisticated, ensuring strong regulatory frameworks will be essential for maintaining safety and public trust.

UK regulators, including the Medicines and Healthcare products Regulatory Agency (MHRA), are already working to adapt existing frameworks to address new forms of digital health technology, particularly artificial intelligence-driven systems.

International benchmarks such as Singapore’s ML4 classification may help inform how regulators collaborate globally and share best practice.

The future of digital health regulation

Singapore’s designation highlights how regulatory systems must evolve alongside technological innovation.

Healthcare delivery is increasingly moving into homes and communities, supported by connected devices and digital platforms. This shift places new demands on regulators, who must oversee technologies that rely on data, software updates and cloud-based infrastructure.

Countries with advanced regulatory systems may also play a greater role internationally by acting as reference authorities for others reviewing medical technologies.

For developers of care technology, stronger global alignment could also make it easier to bring innovations to multiple markets while maintaining high safety standards.